Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis

To clarify the effects of follow-on therapy after denosumab (DMAb) discontinuation.In this retrospective, multicenter study, postmenopausal patients with osteoporosis who were previously treated by oral bisphosphonates (BP) (Changes in LS BMD at 1.5 years after final DMAb administration were -2.7% in the RAL, 0.7% in the wmBP, and 1.9% in the ZOL (These results may contribute to the selection of adequate follow-on therapy after DMAb discontinuation, although further investigations are required.